Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
August 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment...
Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management
August 14, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent.Brent Meadows, MBA, joins as Chief Business Officer (CBO), bringing over 25 years of...
Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study
August 09, 2023 07:30 ET
|
Medicenna Therapeutics Corp.
- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities - Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete...
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
August 08, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today...
Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023
August 04, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today...
Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
August 01, 2023 09:30 ET
|
Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 titled “Interleukin-2 Fusion Proteins and Uses Thereof.”The patent covers a method for enhancing immune cell survival and...
Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights
July 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicitiesMDNA11 clinical update...
Medicenna Presents at National Brain Tumor Society's Research Round Table
July 25, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Medicenna's President and CEO, Dr. Fahar Merchant, was invited to participate and present at the Brain Cancer Research Roundtable organized by the National Brain Tumor Society (“NBTS”)The focus of the...
Medicenna Extends Period to Exercise Certain Warrants
July 05, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, July 05, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced...